BeyondSpring/$BYSI
1D1W1MYTD1Y5YMAX
About BeyondSpring
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
- Ticker
- $BYSI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- Florham Park, United States
- Website
- beyondspringpharma.com
BeyondSpring Metrics
BasicAdvanced
$30M
-
-$0.17
-
-
Price and volume
Market cap
$30M
52-week high
$2.44
52-week low
$0.67
Average daily volume
1.4M
Financial strength
Current ratio
0.698
Quick ratio
0.46
Total debt to equity
-0.475
Profitability
EBITDA (TTM)
-8.386
Effective tax rate (TTM)
-4.24%
Management effectiveness
Return on assets (TTM)
-22.86%
Return on equity (TTM)
31.19%
Valuation
Price to book
-0.83
Price to tangible book (TTM)
-0.83
Price to free cash flow (TTM)
-1.755
Free cash flow yield (TTM)
-56.99%
Free cash flow per share (TTM)
-0.41
Growth
Earnings per share change (TTM)
490.89%
3-year earnings per share growth (CAGR)
-37.21%
10-year earnings per share growth (CAGR)
-11.19%
What the Analysts think about BeyondSpring
Analyst ratings (Buy, Hold, Sell) for BeyondSpring stock.
BeyondSpring Financial Performance
Revenues and expenses
BeyondSpring Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.